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Abstract
Background: Rheumatoid arthritis(RA) is a chronic inflammatory, 
autoimmune polyarthritis, with a prevalence estimated at  one per-
cent of the United States(US) population. Serum bilirubin, because 
of its antioxidant nature, has been conjectured to exert an anti-in-
flammatory biologic effect. The objective of this study is to discern 
whether higher serum Total Bilirubin(TBili) levels are protective 
against RA. 
Methods: This is a secondary analysis of  National Health and 
Nutrition Examination Survey (NHANES) data collected between 
2003-2006. Study participants completed a comprehensive ques-
tionnaire regarding their health history, underwent a physical ex-
amination, and had body fluids collected for laboratory studies. In 
NHANES, to assess for the presence of RA, the following questions 
were asked: “Doctor ever said you had arthritis?” If so, “Which 
type of arthritis”. Statistical analysis was performed, using SAS 
version 9.1, proc survey methods. Participant data were adjusted 
for demographic characteristics as well as risk factors for RA.
Results: NHANES 2003-2006 included 20,470 individuals, chosen 
as a representative sampling of  the entire US population. Exclu-
sion criteria included  age less  than twenty years or liver dysfunc-
tion, defined as history of abnormal liver function tests or liver dis-
ease.   8,147 subjects did not have any exclusion criteria and were 
included in the data analysis. RA is inversely related to the serum 
level of TBili with an odds ratio of 0.679 (95% CI 0.533-0.865) 
and remained significant even after adjusting for age, gender, race, 
education, and tobacco history, with an odds ratio 0.749 (95% CI 
0.575 - 0.976). 
  
Conclusions: Our study supports the hypothesis that higher TBili 
levels are protective against RA. A plausible mechanism for this 
association would be that the anti-oxidant effects of TBili exert a 
physiologic  anti-inflammatory  effect,  which  provides  protection 
against RA. This explanation is supported by prior studies which 
show that higher TBili levels are protective against stroke, athero-
sclerosis, and vasculitis.  Further studies are needed to delineate the 
exact nature of the protective properties of TBili.
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Introduction
Despite great advances in drug development for Rheumatoid 
Arthritis (RA), a large number of patients still tend to rely 
on alternative treatments such as antioxidant therapy and 
diet, suggesting that their RA is still not being adequately 
controlled.  New  therapeutic  approaches  targeting  the  un-
derlying, pathologic inflammation in novel ways have the 
potential to bridge this therapeutic gap. In delineating the 
etiologies of inflammation in RA, the generation of reactive 
oxygen and nitrogen species has been shown to be critical 
to the genesis of this disease [1, 2]. Thus, modalities that 
decrease  production  of  reactive,  oxidative,  inflammatory 
molecules would have direct disease modifying effects. One 
approach that has shown potential is vitamin supplementa-
tion, such as with Vitamin E [3-5]. However, the literature 
remains unclear as to whether this theoretical benefit trans-
lates into clinical improvement in RA patients.
Total Bilirubin (TBili) has been studied as a chemical 
with similar, anti-oxidant properties.  Unlike with Vitamin 
E, a growing body of data exists to show that its anti-inflam-
matory properties do translate into decreased human morbid-
ity [6, 7]. Indeed, literature shows that higher TBili levels 
correlate with a reduced risk of stroke, atherosclerosis, renal 
perfusion  injuries,  and  angiotensin-mediated  hypertension 
[8-13]. Despite this robust body of literature showing the 
benefits of higher TBili levels in varied inflammation-related 
morbidities,  no  literature  exists  investigating  how  higher 
TBili levels impact RA.
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Methods
Survey design
The NHANES survey is a continuous assessment of health 
and nutrition conducted by the Centers for Disease Control 
and Prevention (CDC) and its subsidiary, the National Center 
for Health Statistics (NCHS). Findings from this survey are 
utilized to determine the prevalence of major diseases and 
their risk factors. The NHANES survey consists of house-
hold interviews, physical and dental evaluations, and body 
fluid collections, such as blood and urine, of a representa-
tive sample of the non-institutionalized, United States popu-
lation,  using  a  complex,  stratified,  multistage  probability 
cluster survey design. Older individuals, children, Mexican 
Americans, and African Americans are purposefully over-
represented to insure a pre-specified minimum sample size. 
Sampling weights are used to adjust the cohort distribution 
so that it more closely models the US population. Between 
2003 and 2006, 20,470 subjects participated in the NHANES 
survey process. Those individuals less than 20 years old or 
with liver disease were excluded from data analysis. A to-
tal of 8,147 subjects did not meet any exclusion criteria and 
were included in data analysis.
Laboratory methods
Serum samples were collected and analyzed in a standard-
ized  manner  from  fasting  individuals  as  described  in  the 
White  Sands  Clinical  Laboratory’s  Collection  Procedures 
and Specimen Requirements Manual 8. Blood drawn from 
the examinee’s arm was processed and stored on dry ice at 
-70°C. The analyses were performed with a Beckman Syn-
chron LX20. The serum TBili concentration was assayed us-
ing a timed-endpoint diazo method. This chemical assay is 
predicated on bilirubin reacting with the diazo reagent, in 
the presence of caffeine, benzoate, and acetate as accelera-
tors to form azobilirubin. The assay measurement instrument 
detects changes in light absorbance, at 520 nm wavelength, 
after the chemical reaction has progressed for a fixed time 
interval. 
Definition of variables
NHANES survey interviewers completed an extensive two-
week training course prior to conducting interviews. A large 
percentage of the interview is conducted in both English and 
Spanish. RA was defined based on the subject’s response 
to the following questions: ‘Have you ever been told by a 
Figure 1. Prevalence of serum TBili among the participants.
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doctor that you had arthritis?’ and ‘What type of arthritis?’ 
Liver disease was defined based on a subject’s response to 
the question ‘Have you had liver disease?’  Participants who 
answered ‘yes’ to the question regarding liver disease or who 
had AST values greater than 50 ng/ml on serum studies, or 
ALT values greater than 50 ng/ml on serum studies, were 
excluded  from  data  analysis.  Other  co-variables  included 
were self-reported age, gender, race/ethnicity, smoking sta-
tus, education status, and marital status. BMI was calculated 
from height and weight measurements, and placed into 3 cat-
egories based on the CDC criteria of normal (less than 25), 
overweight (25 - 29.9) and obese (greater than 30).
Statistical analysis
NHANES uses a complex, stratified, multi-state probability-
cluster sampling survey design. Due to the complexity of 
this survey’s design, we used SAS version 9.1’s (Cary, NC) 
PROCSURVEY  methodology.  A  Jackknife  Replacement 
method was used to estimate the sample variance. Logistic 
regression models were created to look at the unadjusted 
association between RA and the TBili. Adjusted regression 
models, using the variables age, gender, race, marital status, 
education, smoking and BMI, were also derived.
 
Results
Our  analysis  showed  the  data  to  be  normally-distributed, 
with a right tail (Fig. 1). The mean TBili level was 11.99 
micromoles per liter with a standard deviation of 5.28.  
Based on prior studies investigating the disease preven-
tative effects of TBili, our analysis stratified TBili levels as 
either less than or greater than 11 micromoles per liter [11]. 
The demographic characteristics of these two groups were 
then compared (Table 1). With respect to the age-adjusted 
prevalence,  males  had  higher  TBili  levels  while  females 
tended  to  have  levels  less  than  11  micromoles  per  liter. 
Among participants with a BMI less than 30, a higher pro-
portion of subjects had higher TBili levels. 
With respect to RA, a greater proportion of subjects who 
did not report any history of RA had a TBili above 11 mi-
cromoles per liter (55.93% with SE of 0.92). Although there 
was a trend toward more patients in the RA stratification also 
having lower TBili levels (less than 11 micromoles per li-
ter), it did not reach statistical significance. However, a sta-
tistically-significant, unadjusted association between higher 
TBili levels and RA did exist (OR 0.68, 95% CI 0.53 - 0.87). 
The relationship remained statistically significant after ad-
justing for age, sex, race, married status, education (Fig. 2), 
BMI and smoking (OR 0.75, 95% CI 0.58 - 0.98). 
Discussion
  
Previous studies have suggested that the antioxidant proper-
ties of TBili have disease preventative effects with respect to 
stroke, coronary artery disease and peripheral vascular dis-
ease [8-11]. In this study, we found that this inverse relation 
between higher TBili levels and disease prevalence extends 
to RA as well. 
The exact nature of this protective effect is not clear. We 
do know that the inflammation inherent to RA results from 
immunological reactions involving the activation of granu-
locytes, macrophages and lymphocytes [1]. These inflam-
matory cells, in the synovial fluid, are in an activated state, 
releasing oxygen-derived free radicals that are lethal to the 
joint tissue [2]. One possibility for the protective effect of 
TBili with regard to RA risk suggests that Bilirubin clears 
peroxyl radicals, decreases oxidative stress and by binding 
to serum albumin can prevent in-vitro oxidation of albumin-
bound fatty acids [13-15].  
Furthermore,  unconjugated  Bilirubin  and  Biliverdin 
have been shown to exhibit immune protective effects on 
murine liver and cardiac grafts. In the case of Biliverdin, this 
effect has been shown to be mediated by suppression of IL-2 
production, via inhibition of nuclear factor. Recent research 
has shown that intracellular redox cycling of bilirubin to 
biliverdin, a metabolite of bilirubin, may be important for 
cytoprotection [3].  
In reviewing the strengths and weaknesses of this study, 
this study’s large sample size would lend itself to increased 
resolution of small differences in the groups studied. Fur-
thermore, use of data from NHANES facilitates investiga-
tion of the interaction among multiple co-variables and its 
study design facilitates generalization to the US population, 
as a whole. Since our analysis is based on data derived from 
a survey, there will be an inherent inability to determine tem-
poral association of higher TBili levels and RA. In addition, 
this study is limited by the survey participants self-report 
Figure 2. Odds ratio of RA in subjects with higher TBili levels in 
comparison to subjects with lower TBili levels.  Note:  odds ratio 
of RA in lower TBilli subjects defined as 1.
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of RA, possibly leading to inaccurate estimates of disease 
prevalence based on participant misconceptions regarding 
their level of health. The laboratory analysis of participant 
blood did not include fractionation of bilirubin levels. Thus, 
it is not possible to discern whether the anti-oxidant effects 
of TBili are a combined phenomenon versus the sole effect 
of Indirect or Direct Bilirubin. 
In conclusion, higher serum TBili levels are negatively 
associated with RA. These findings introduce the possibil-
ity of a therapeutic role of bilirubin as an anti-inflammatory 
agent, alongside pharmacotherapy, to reduce the process of 
joint destruction. Further studies, particularly cohort stud-
ies, are needed to confirm this association and to investigate 
approaches to manipulate the TBili level for the patient’s 
benefit.
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